ArticleBrazilian journal of veterinary medicine2023
Unenriched skin microbiota transplantation for cats: new road story for treating feline atopic skin syndrome.
Article in Brazilian journal of veterinary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Skin microbiome engineering: Challenges and opportunities in skin diseases treatment.iMetaOmics · 2025Review
- Microbiota transplantation.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Manipulation of skin biogeography has been the subject of study by the present authors for a very long while. Previous description and report identified the benefical application of skin microbiota transplantation (SMT) by the same researcher group, whom described unenriched skin microbiota transplantation at clinical veterinary practice for the first time among dogs. This study to our knowledge again for the first time reported herein aimed to investigate Un-smt application for treatment of feline atopic skin syndrome (FASS). This novel treatment intervention was performed similarly to previous description and methodology by use of Nivea Refining Clear-Up Strips (Ni-RcUs) either in autologue or heterologue route. Clinical biomarker for detecting the efficacy of Un-smt via Ni-RcUs evolved epidermal corneometric analytes (i.e. epidermal hydration and pH), relevant clinical scores The Feline Dermatitis Extent and Severity Index (FeDESI) and Visual Analogue Scale (VAS pruritus) and clinical observations performed weekly, at least. Both FeDESI and VAS pruritus scores were changed in relationship with smt. Pre-treament day 0 FeDESI scores (median ± SE) (72.5 ± 9.34), were significantly (p=0.001) higher than scores on day 10 (13.5 ± 2.55) switching the severity of the disease in all cases. Besides day 0 VAS pruritus scores were 6.0 ± 0.49 (median ± SE) (prior to treatment), whereas owner VAS pruritus score was decreased to 2.0 ± 0.34 (median ± SE) significantly (p=0.001). There were no side effects attributable to treatment applications. All cases were monitored for 6 months after completion of treatment in which no recurrence was observed. As a preliminary conclusion with selected number of cats with FASS, Un-smt with Ni-RcUs should be novel strategy for manuplating skin microbiome with treatment success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.